Open access
Open access
Powered by Google Translator Translator

Psychiatry

Perspective: Nervous system consequences of COVID-19.

21 Jan, 2022 | 10:10h | UTC

Nervous system consequences of COVID-19 – Science

Related:

Perspective | Post-acute neurological consequences of COVID-19: an unequal burden – “COVID-19 and its neurological consequences particularly burden marginalized communities, and so can only be effectively treated by advancing health equity”.

Review: Counting the neurological cost of COVID-19.

Infection with Covid-19 carries a much higher risk of developing neurological complications than Covid-19 vaccines.

M-A: Frequency of Neurologic Manifestations in COVID-19 – up to one-third of patients (89% hospitalized) experienced at least one neurological manifestation.

Neurological Effects of COVID-19 in Children.

Cohort study: Neurological manifestations of SARS-CoV-2 infection in hospitalized children and adolescents in the UK – “around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection”.

International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.

Short review: Neurological complications of COVID-19.

2 new meta-analysis detail neurologic and psychiatric conditions in COVID-19.

M-A: Encephalitis as Neurological Complication of COVID‐19.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditionsEight out of ten people hospitalized with COVID-19 develop neurological problems – the most common self-reported symptoms included headache (37%) and anosmia or ageusia (26%).

[Preprint] Frequency of neurological manifestations in COVID-19: a systematic review and meta-analysis of 350 studies – up to one-third of COVID-19 patients analyzed in this review, 89% of whom were hospitalized, experienced at least one neurological manifestation

 

Commentary on Twitter

 


Systematic Review: In people with Alzheimer’s disease and vascular dementia with agitation and psychosis, atypical antipsychotics probably reduce agitation slightly (moderate‐certainty evidence) but probably have a negligible effect on psychosis or risk of any adverse event.

21 Jan, 2022 | 09:50h | UTC

Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia – Cochrane Library

Summary: Do antipsychotic medicines reduce  agitated behaviour and psychotic symptoms in people with Alzheimer’s disease and vascular dementia? – Cochrane Library

 


Meta-analysis of randomized controlled trials: Drug treatment for panic disorder with or without agoraphobia.

20 Jan, 2022 | 09:06h | UTC

Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials – The BMJ

 


RCT: Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia.

19 Jan, 2022 | 08:11h | UTC

Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study – The Lancet Neurology (link to abstract – $ for full-text)

Commentary: Mixed Salts Oxybate Improves Daytime Performance in Individuals with Idiopathic Hypersomnia – Practical Neurology

 


RCT: Ketamine induced remission in 46% of patients but was NOT non-inferior to electroconvulsive therapy for the treatment of hospitalized patients with unipolar depression.

16 Jan, 2022 | 23:01h | UTC

Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT) – International Journal of Neuropsychopharmacology

News Release: ECT more effective than ketamine in severe depression – Lund University

 

Commentary on Twitter

 


Cluster randomized trial: no added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis.

16 Jan, 2022 | 22:59h | UTC

No added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis: a cluster randomised trial – Arthritis & Rheumatism

 


Systematic Review: Ketamine for the treatment of mental health and substance use disorders.

14 Jan, 2022 | 08:08h | UTC

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review – BJPsych Open

Commentaries:

Ketamine therapy swiftly reduces depression and suicidal thoughts – University of Exeter

Ketamine May Quickly Ease Tough-to-Treat Depression – HealthDay

 


M-A: Combined oral contraceptives may improve overall premenstrual symptomatology but are not helpful for premenstrual depressive symptoms.

14 Jan, 2022 | 07:49h | UTC

Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials – American Journal of Obstetrics & Gynecology

Commentary: ‘Optimal’ treatment for premenstrual depressive symptoms remains elusive – Healio (free registration required)

 


The COVID generation: how is the pandemic affecting kids’ brains?

13 Jan, 2022 | 08:53h | UTC

The COVID generation: how is the pandemic affecting kids’ brains? – Nature

 


Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

13 Jan, 2022 | 08:42h | UTC

Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 – The Lancet Psychiatry

Invited Commentary: The true global disease burden of mental illness: still elusive – The Lancet Psychiatry (free registration required)

 


Phase 2 RCT: Adjunctive ketamine with relapse prevention–based psychological therapy shows promise for the treatment of alcohol use disorder.

12 Jan, 2022 | 08:42h | UTC

Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder – The American Journal of Psychiatry (link to abstract – $ for full-text)

Commentary: People With AUD May Benefit From Combination of Ketamine, Mindfulness Therapy – Psychiatric News Alert

 


Review | Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop.

11 Jan, 2022 | 02:16h | UTC

Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop – Drug and Therapeutics Bulletin

 

Commentary from the author on Twitter (thread – click for more)

 


M-A: Fatigue and cognitive impairment in Post-COVID-19 Syndrome.

11 Jan, 2022 | 01:28h | UTC

Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis – Brain, Behavior, and Immunity

 


RCT: Long-term supplementation with marine Omega-3 fatty acids does not reduce the risk of depressive symptoms.

8 Jan, 2022 | 23:10h | UTC

Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary: Clinical trial reveals that omega-3 fish oil supplements do not help prevent depression – Massachusetts General Hospital

 


RCT: Vitamin D supplementation does not improve outcomes in people with early psychosis.

8 Jan, 2022 | 22:52h | UTC

Effect of Vitamin D Supplementation on Outcomes in People With Early Psychosis: The DFEND Randomized Clinical Trial – JAMA Network Open

 


AAP Interim guidance on supporting the emotional and behavioral health needs of children, adolescents, and families during the COVID-19 pandemic.

17 Dec, 2021 | 09:57h | UTC

Interim Guidance on Supporting the Emotional and Behavioral Health Needs of Children, Adolescents, and Families During the COVID-19 Pandemic – American Academy of Pediatrics

Commentary: AAP Issues Guidance for Children’s Emotional Needs During COVID-19 – HealthDay

 


Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions.

14 Dec, 2021 | 08:44h | UTC

News release: Cannabis use could cause harmful drug interactions – Washington State University

Original Study: Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions – Drug Metabolism and Disposition

 


Perspective: Alcohol-related harm is a public health issue, not a lifestyle choice.

14 Dec, 2021 | 08:41h | UTC

Alcohol-related harm is a public health issue, not a lifestyle choice – Health Policy Watch

Related:

COVID-19 pandemic and alcohol consumption: Impacts and interconnections – Toxicology Reports

National, Regional, and Global Burdens of Disease Attributable to Alcohol Use

Study: Alcohol Use and Burden for 195 Countries and Territories

Study: The Global Burden of Disease Attributable to Alcohol and Drug Use

Study: Global Alcohol Exposure Between 1990 and 2017 and Forecasts Until 2030

Analysis: Prioritizing Action on Alcohol for Health and Development

5000 alcohol-related cancer deaths could be prevented every year by doubling alcohol taxes in the European Region, says WHO/Europe.

Global burden of cancer attributable to alcohol consumption – “Globally, an estimated 741.300, or 4·1% of all new cases of cancer in 2020 were attributable to alcohol consumption”.

Research: Contribution of alcohol use disorders to the burden of dementia

 


Review: Neuropsychiatric assessment and management of the ICU survivor.

10 Dec, 2021 | 10:01h | UTC

Neuropsychiatric assessment and management of the ICU survivor – Cleveland Clinic Journal of Medicine

 


Outcomes associated with caustic ingestion among 1198 adults in a national prospective database in France.

9 Dec, 2021 | 10:19h | UTC

Outcomes Associated With Caustic Ingestion Among Adults in a National Prospective Database in France – JAMA Surgery (free for a limited period)

Invited commentary: Caustic Ingestion—The Haves and the Have Nots (free for a limited period)

 

Commentary on Twitter

 


Benzodiazepines: Uses, dangers, and clinical considerations.

30 Nov, 2021 | 09:59h | UTC

Benzodiazepines: Uses, Dangers, and Clinical Considerations – Neurology International

 


M-A: Psychiatric disorders in individuals born very preterm / very low-birth weight.

28 Nov, 2021 | 21:11h | UTC

Psychiatric disorders in individuals born very preterm / very low-birth weight: An individual participant data (IPD) meta-analysis – EClinicalMedicine

 


Fatigue as the chief complaint: epidemiology, causes, diagnosis, and treatment.

28 Nov, 2021 | 21:05h | UTC

Fatigue as the Chief Complaint: Epidemiology, Causes, Diagnosis, and Treatment – Deutsches Ärzteblatt International

Related: NICE Guideline | Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management.

 


Systematic Review: Quantifying anticholinergic burden and sedative load in older adults with polypharmacy.

26 Nov, 2021 | 09:58h | UTC

Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models – Drugs & Aging

 

Commentary on Twitter

 


Systematic Review: Insufficient evidence to recommend Omega‐3 fatty acids for depression in adults.

26 Nov, 2021 | 09:54h | UTC

Omega‐3 fatty acids for depression in adults – Cochrane Library

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.